Table 17.
Studies on intravitreal methotrexate (demographics and clinical features)
| Study | Period of study | Study design | Study duration | Number of participants/eyes | Demographics
|
Clinical features of participants
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) |
Sex (female) |
Diagnosis of study eye | Details | Laterality of condition | Duration of uveitis | Presence of other ocular conditions | Previous uveitis treatment | Mean baseline VA (logMAR) | Mean baseline vitreous haze | Mean baseline CRT/CFT/CMT (μm) | |||||
| Taylor et al37 | – | Prospective, consecutive, interventional case series | Follow-up of 6 months in 80% | 15 eyes of 15 patients | 50 (range, 25–68) | 47% | Active NIU ± CME, all steroid responders | 27% anterior uveitis with long-standing CME, 53% intermediate uveitis with active vitritis and CME, 20% panuveitis with vitritis and CME | 100% unilateral | Median duration of CME in current disease episode: 6 months (range, 1–54 months) | 20% vitrectomized eyes, 67% pseudophakic | 47% on systemic medication at study entry. 27% eyes had previous IVTA injection | 1.06±0.12 | 1.40±0.16 | 425±57 |
| Taylor et al38 | – | Multicenter, retrospective interventional case series | Mean follow-up: 11.2 months (range, 3–28 months) | 38 eyes of 30 patients | Median: 46 (range, 20–73) | 53% | NIU | 18% chronic anterior uveitis with CME, 42% intermediate uveitis or pars planitis, 39% posterior uveitis or panuveitis | – | – | – | 47% on systemic medication at time of study entry | 0.60 (range, 0.10–1.30) | – | 436±33 (range, 227–1,173) |
Note: “–”, data not available.
Abbreviations: CME, cystoid macular edema; CFT, central foveal thickness; CMT, central macular thickness; CRT, central retinal thickness; IVTA, intravitreal triamcinolone acetonide; logMAR, logarithm of Minimal Angle of Resolution; NIU, noninfectious uveitis; VA, visual acuity.